ReviewDiabetes2020
Energy Regulation Mechanism and Therapeutic Potential of Asprosin.
Review in Diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Pooled it
- Effects of exercise and dietary interventions on asprosin, leptin, and lipid metabolism in males with abdominal obesity, a randomized controlled trial.Scientific reports · 2024Trial
- Identification and evolutionary analysis of insect fibrillin with their closely related family proteins.PeerJ · 2026Article
- Serum asprosin levels as a potential prognostic biomarker in COVID-19: insights for future respiratory viral pandemics.BMC infectious diseases · 2025Article
- Chemerin and Asprosin as Promising Biomarkers of Metabolic Syndrome: A Scoping Review.Current obesity reports · 2025Article
- Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Association analysis between serum asprosin and metabolic characteristics, Complications in type 2 diabetic patients with different durations.Journal of diabetes investigation · 2024Article
- Asprosin promotes vascular inflammation via TLR4-NFκB-mediated NLRP3 inflammasome activation in hypertension.Heliyon · 2024Article
- Adipokines and their role in acute pancreatitis.Journal of medical biochemistry · 2024Article
- A study of the relationship between serum asprosin levels and MAFLD in a population undergoing physical examination.Scientific reports · 2024Article
- Asprosin is positively associated with metabolic syndrome in hemodialysis patients: a cross-sectional study.Renal failure · 2023Article
- Gonacin: A germ cell-derived hormone with glucogenic, orexigenic, and gonadal activities.iScience · 2023Article
- Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Serum Asprosin Concentrations in Children with Prader-Willi Syndrome: Correlations with Metabolic Parameters.Journal of clinical medicine · 2022Article
- A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes.Journal of the National Cancer Institute · 2022Article
- Association Between Serum Asprosin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus in the Community: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Quercetin targets VCAM1 to prevent diabetic cerebrovascular endothelial cell injury.Frontiers in aging neuroscience · 2022Article
- Asprosin is associated with anorexia and body fat mass in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- A state of the art review on the novel mediator asprosin in the metabolic syndrome.Porto biomedical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic studies of patients with neonatal progeroid syndrome led to the discovery of the novel fasting-induced, glucogenic, and orexigenic hormone named asprosin, the C-terminal cleavage product of profibrillin. Upon secretion, asprosin travels to the liver, where it exerts a glucogenic effect through OR4M1, an olfactory G-protein-coupled receptor. It also crosses the blood-brain barrier to stimulate appetite-modulating neurons in the arcuate nucleus of the hypothalamus, exerting an orexigenic effect via an as yet unidentified receptor. Specifically, it stimulates appetite by activating orexigenic AgRP neurons and inhibiting anorexigenic POMC neurons. Studies have also focused on the therapeutic potential of inhibiting asprosin for treatment of obesity and type 2 diabetes, both of which are characterized by high levels of circulating asprosin. It has been shown that anti-asprosin monoclonal antibodies reduce blood glucose, appetite, and body weight, validating asprosin as a therapeutic target. Current work aims to uncover key features of the asprosin biology such as the identification of its neuronal receptor, identification of the secretion mechanism from adipose tissue, and development of anti-asprosin monoclonal antibodies as diabetes and obesity therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.